National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Vortioxetine (Brintellix®)

Vortioxetine (Brintellix®) is indicated for the treatment of major depressive episodes in adults.

Rapid Review

Commenced Completed Outcome
01/10/2014 14/11/2014 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
16/02/16  16/11/2016 Reimbursement Not Recommended


The HSE has approved reimbursement following confidential price negotiations October 2017.